New drug cocktail aims to shrink lung tumors in Late-Stage trial

NCT ID NCT07246863

First seen Dec 18, 2025 · Last updated May 12, 2026 · Updated 17 times

Summary

This study tests whether adding the experimental drug visugromab to standard immunotherapy and chemotherapy can shrink tumors better than chemotherapy alone in people with advanced non-squamous lung cancer. About 131 participants who have already tried one prior treatment will receive different combinations of these drugs. The goal is to find a more effective second-line option for this hard-to-treat cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cantonal Hospital Saint Gallen, Clinic of Oncology and Hematology

    RECRUITING

    Sankt Gallen, CH-9007, Switzerland

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Clinics Essen-Mitte

    RECRUITING

    Essen, North Rhine-Westphalia, 45136, Germany

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Duke University Medical Center

    NOT_YET_RECRUITING

    Durham, North Carolina, 27710, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Evangelical Hospital Bethel, Clinic for Internal Medicine, Hematology/Oncology, Palliative Medicine Johannesstift

    RECRUITING

    Bielefeld, North Rhine-Westphalia, 33611, Germany

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Hospital Esslingen GmbH

    RECRUITING

    Esslingen am Neckar, Baden-Wurttemberg, 73730, Germany

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Institute of Romagna for Cancer Research "Dino Amadori" - IRCCS IRST

    RECRUITING

    Forlì, Emilia-Romagna, 47014, Italy

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Local Health Unit of Romagna - Santa Maria delle Croci Hospital of Ravenna, Onco-Hematology Department

    RECRUITING

    Ravenna, 48121, Italy

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Regional University Hospital of Malaga

    RECRUITING

    Málaga, Andalusia, 29010, Spain

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • USC Norris Comprehensive Cancer Center

    RECRUITING

    Los Angeles, California, 90033, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University Hospital 12 de Octubre

    RECRUITING

    Madrid, Madrid, 28041, Spain

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University Hospital Basel

    RECRUITING

    Basel, 4031, Switzerland

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University Hospital Lucus Augusti (HULA)

    RECRUITING

    Lugo, 27003, Spain

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University Hospital Wuerzburg, Clinic and Polyclinic II for Gastroenterology, Hematology, Internal Oncology, Stem Cell Therapies, Hepatology, Infectiology, Psychosomatics and Rheumatology/ Clinical Immunology

    RECRUITING

    Würzburg, Bavaria, 97080, Germany

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University Hospital of Jaen

    RECRUITING

    Jaén, Andalusia, 23007, Spain

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Alabama at Birmingham (O'Neal Comprehensive Cancer Center)

    NOT_YET_RECRUITING

    Birmingham, Alabama, 35294-3300, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.